Skip to Content

Press Releases

Date Title and Summary Additional Formats
Aug 08, 2022
Second quarter revenue of $18.8 million Completed $250 million strategic cash infusion from Casdin Capital and Viking Global   Upgraded management team and added board members to bring significant sector and operational expertise to the company   Commenced restructuring program with the explicit
Jul 25, 2022
SOUTH SAN FRANCISCO, Calif. , July 25, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose –  unleashing tools to accelerate breakthroughs in human health – today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after
May 05, 2022
SOUTH SAN FRANCISCO, Calif. , May 05, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose –  unleashing tools to accelerate breakthroughs in human health  – today announced financial results for the first quarter ended March 31, 2022 .   “The end of first quarter
Apr 22, 2022
SOUTH SAN FRANCISCO, Calif. , April 22, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose –  unleashing tools to accelerate breakthroughs in human health – today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022, after
Apr 11, 2022
Capacity to Process 100-Plus Samples per Week, with 1.6x Lower Limit of Detection SOUTH SAN FRANCISCO, Calif. , April 11, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose –  unleashing tools to accelerate breakthroughs in human health – today announced the
Apr 05, 2022
SOUTH SAN FRANCISCO, Calif. , April 05, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (f/k/a Fluidigm Corporation) (Nasdaq:FLDM) today announced, as required by Nasdaq Stock Market Rules, the grant of equity inducement awards to its new executive officers Michael Egholm , the Company’s new
Apr 04, 2022
New Trading Symbol (NASDAQ:LAB) Expected to be Effective April 6, 2022 Appoints New Management Team and Additional Board Members with Significant Experience to Reinvigorate Growth and Enhance Product Portfolio Embarks on New Chapter of Focused Execution and Growth SOUTH SAN FRANCISCO, Calif.
Apr 01, 2022
SOUTH SAN FRANCISCO, Calif. , April 01, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today announced that its stockholders have voted to approve all of the proposals related to the previously announced strategic capital infusion from leading life sciences investors Casdin Capital,
Mar 29, 2022
Caligan Partners to Vote “FOR” Casdin and Viking Transaction and All Other Fluidigm Proposals at the Special Meeting to be Reconvened on April 1, 2022 Fluidigm Board to Appoint Frank Witney , a Director Candidate Recommended by Caligan, if Casdin and Viking Transaction Closes Company Urges ALL
Mar 28, 2022
Company Urges ALL Stockholders to Vote “FOR” the Proposals at the Special Meeting Parties to Terminate the Purchase Agreements if Stockholder Approval is Not Received on April 1 SOUTH SAN FRANCISCO, Calif. , March 28, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that